Insider Buying: STAAR Surgical (NASDAQ:STAA) Major Shareholder Acquires 21,155 Shares of Stock

STAAR Surgical (NASDAQ:STAA - Get Free Report) major shareholder Broadwood Partners, L.P. bought 21,155 shares of the firm's stock in a transaction on Tuesday, January 14th. The stock was purchased at an average cost of $21.46 per share, with a total value of $453,986.30. Following the completion of the acquisition, the insider now directly owns 10,869,786 shares of the company's stock, valued at approximately $233,265,607.56. The trade was a 0.20 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The shares were purchased at an average cost of $21.50 per share, with a total value of $176,751.50.
• On Wednesday, December 18th, Broadwood Partners, L.P. acquired 23,000 shares of STAAR Surgical stock. The stock was acquired at an average cost of $24.33 per share, for a total transaction of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. bought 53,500 shares of STAAR Surgical stock. The stock was acquired at an average cost of $24.24 per share, with a total value of $1,296,840.00.

STAAR Surgical Trading Up 0.6 %

NASDAQ STAA traded up $0.14 on Thursday, hitting $21.85. 531,485 shares of the company traded hands, compared to its average volume of 732,698. The business's 50 day moving average price is $25.72 and its 200-day moving average price is $32.16. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of 49.66 and a beta of 0.63. STAAR Surgical has a 52-week low of $21.13 and a 52-week high of $52.68.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Arcadia Investment Management Corp MI bought a new stake in STAAR Surgical during the 3rd quarter worth approximately $37,000. Quarry LP purchased a new stake in shares of STAAR Surgical in the third quarter worth $50,000. Quest Partners LLC bought a new stake in shares of STAAR Surgical during the 3rd quarter valued at $128,000. Canada Pension Plan Investment Board bought a new stake in shares of STAAR Surgical during the 2nd quarter valued at $129,000. Finally, Van ECK Associates Corp boosted its holdings in STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier's stock worth $129,000 after buying an additional 393 shares during the period. 96.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on STAA shares. Stephens raised STAAR Surgical to a "hold" rating in a research report on Monday, December 2nd. Needham & Company LLC reiterated a "hold" rating on shares of STAAR Surgical in a research note on Tuesday, January 7th. Finally, Canaccord Genuity Group lowered their price objective on shares of STAAR Surgical from $31.00 to $28.00 and set a "hold" rating on the stock in a research report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, STAAR Surgical has a consensus rating of "Hold" and a consensus target price of $42.83.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.